SCHEMBL25306337

SCHEMBL25306337

O=C(c1cccnc1)c1ccc(F)cc1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.49
ATM Q13315 1/20 0.49
ALDH1A1 P00352 3/20 0.48
RAB9A P51151 2/20 0.46
AGTR1 P30556 1/20 0.46
OPRK1 P41145 1/20 0.46
GAA P10253 3/20 0.46
APP P05067 1/20 0.46
HCAR3 P49019 1/20 0.46
HCAR2 Q8TDS4 1/20 0.46
MEN1 O00255 2/20 0.45
USP2 O75604 1/20 0.45
KEAP1 Q14145 1/20 0.45
NFE2L2 Q16236 1/20 0.45
F7 P08709 1/20 0.45
F3 P13726 1/20 0.45
SARM1 Q6SZW1 1/20 0.45
SIRT2 Q8IXJ6 1/20 0.45
SIRT6 Q8N6T7 1/20 0.45
SIRT1 Q96EB6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13347759 0.86 KMT2A (0.50) KMT2AATMALDH1A1RAB9AAGTR1
SCHEMBL22671925 0.84 KMT2A (0.65) KMT2AALDH1A1RAB9AGAAAPP
SCHEMBL30203906 0.84 KMT2A (0.65) KMT2AALDH1A1RAB9AGAAAPP
SCHEMBL9002920 0.82 KMT2A (0.51) KMT2AALDH1A1RAB9AGAAAPP
SCHEMBL25308673 0.82 KMT2A (0.42) KMT2AATMALDH1A1RAB9AAGTR1
SCHEMBL30070815 0.80 GAA (0.68) KMT2AATMALDH1A1RAB9AGAA
SCHEMBL5389980 0.80 GAA (0.68) KMT2AATMALDH1A1RAB9AGAA
SCHEMBL25308448 0.80 MAPT (0.50) KMT2AATMALDH1A1MKNK1MKNK2
SCHEMBL22426419 0.79 ALDH1A1 (0.56) KMT2AALDH1A1RAB9AGAAAPP
SCHEMBL10487079 0.78 AGTR1 (0.57) KMT2AATMALDH1A1RAB9AAGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4466266-B1 FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS TRANSNEURAL THERAPEUTICS INC (US) 2026-04-08 EP disclosed
US-12486268-B2 Fused heterocycles as 5-HT2A receptor agonists Transneural Therapeutics, Inc. (US) 2025-12-02 US disclosed
US-12459944-B2 Fused heterocycles as 5-HT2A receptor agonists Transneural Therapeutics, Inc. (US) 2025-11-04 US disclosed
US-20250243199-A1 FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS Transneural Therapeutics, Inc. (US) 2025-07-31 US disclosed
US-20240425503-A1 FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS Transneural Therapeutics, Inc. 2024-12-26 US disclosed
EP-4466266-A1 FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS Transneural Therapeutics, Inc. (US) 2024-11-27 EP disclosed
WO-2023141225-A1 FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS ONSERO THERAPEUTICS INC. (US) 2023-07-27 WO disclosed
WO-2023141225-A1 FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS ONSERO THERAPEUTICS INC. (US) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12459944-B2 Fused heterocycles as 5-HT2A receptor agonists HTR2A, HTR2C, HTR5A KMT2A 1097/4885ATM 3469/4885ALDH1A1 760/4885
US-20250243199-A1 FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS HTR2A, HTR2C, HTR5A KMT2A 1097/4885ATM 3469/4885ALDH1A1 760/4885
US-20240425503-A1 FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS HTR2A, HTR2C, HTR1A KMT2A 225/4885ATM 3916/4885ALDH1A1 659/4885
US-12486268-B2 Fused heterocycles as 5-HT2A receptor agonists HTR2A, HTR2C, HTR5A KMT2A 1097/4885ATM 3469/4885ALDH1A1 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.